Multiple Self-Healing Squamous Epithelioma (MSSE):A Digenic Trait Associated with Loss of Function Mutations in <i>TGFBR1</i> and Variants at a Second Linked Locus on the Long Arm of Chromosome 9 by Goudie, David
                                                                    
University of Dundee









Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Goudie, D. (2020). Multiple Self-Healing Squamous Epithelioma (MSSE): A Digenic Trait Associated with Loss
of Function Mutations in TGFBR1 and Variants at a Second Linked Locus on the Long Arm of Chromosome 9.
Genes, 11(12), [1410]. https://doi.org/10.3390/genes11121410
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 20. Apr. 2021
genes
G C A T
T A C G
G C A T
Review
Multiple Self-Healing Squamous Epithelioma
(MSSE): A Digenic Trait Associated with Loss of
Function Mutations in TGFBR1 and Variants at a
Second Linked Locus on the Long Arm of
Chromosome 9
David Goudie
Regional Genetics Service, NHS Tayside, Dundee DD1 9SY, UK; david.goudie@nhs.scot
Received: 23 October 2020; Accepted: 25 November 2020; Published: 26 November 2020 
Abstract: MSSE (Ferguson-Smith disease) is a rare familial condition in which multiple skin tumors
resembling squamous carcinomas invade locally and then regress spontaneously after several months,
leaving disfiguring scars. We review evidence from haplotype studies in MSSE families with common
ancestry that the condition is caused by loss of function mutations in TGFBR1 interacting with
permissive variants at a second linked locus on the long arm of chromosome 9. The spectrum
of TGFBR1 mutations in MSSE and the allelic disorder Loeys Dietz syndrome (characterized by
developmental anomalies and thoracic aortic aneurysms) differ. Reports of patients with both MSSE
and Loeys Dietz syndrome are consistent with variants at a second locus determining whether
self-healing epitheliomas occur in patients with the loss of function mutations found in most MSSE
patients or the missense mutations in the intracellular kinase domain of TGFBR1 that characterize
Loeys Dietz syndrome.
Keywords: multiple self-healing squamous epithelioma; MSSE; TGFBR1; Loeys Dietz syndrome
1. Clinical Features
Multiple self-healing squamous epithelioma (MSSE, OMIM 132800) is a rare familial form of skin
cancer characterized by multiple skin tumors of the face and limbs. These lesions heal spontaneously
after several months leaving characteristic pitted scars if they are not excised.
MSSE was first described in a 23 years old Scottish coal miner [1]. MSSE can be variable in its
severity and age of onset but his history is typical of many patients. He developed multiple lesions
on his legs aged 16. Each tumor started “at first as a reddish macule, became papular, enlarged,
ulcerated and ultimately healed leaving pitted scars. The individual lesions lasted for months, and fresh
ones appeared in numbers rather more than sufficient to balance the healing so that the count of active
lesions slowly increased. His face and ears soon became affected, and one or two lesions appeared on
his arms and thighs”.
The condition can be very disfiguring in severely affected individuals. Some affected individuals
have one or two tumors during their lifetime while others have had over 100 primary skin tumors [2].
The age of onset of a first tumor is variable ranging from 8 to over 70 years (median 28 years). As each
tumor involutes it forms a horny plug that falls out often leaving a deep pit with irregular, over-hanging
edges (Figure 1). Lesions on the limbs are typically larger than those on the face, scalp and ears,
and leave flat scars. Tumors arise most frequently on the sun-exposed skin of the head, neck and
limbs. The nose, ears and circumoral regions are most frequently affected. The trunk is seldom affected.
Palmar and plantar skin are not affected suggesting that the tumors may arise from hair follicles [2].
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Figure 1. A small (5 mm) self-healing epithelioma with a central keratin plug adjacent to a pitted scar 
at the site of a lesion that resolved spontaneously. 
The MSSE tumors have a similar histological appearance to well-differentiated squamous 
carcinomas, with invasion deep into the dermis. Lymphocytes often infiltrate the tumors but their 
role in tumor resolution is not known. Invasive epithelial columns show central keratinization with 
the formation of cornified ‘nests’, which as the tumor involutes, coalesce into a horny plug (Figures 2 
and 3). The base of the resolving lesion shows marked fibrosis of the dermis with loss of elastic 
fibers. The skin tumors follow a similar clinical course to sporadic keratoacanthomas. MSSE tumors 
can usually be distinguished from keratoacanthomas because of the occurrence of multiple lesions, 
the earlier ages at which tumors develop and the familial nature of the condition. The diagnosis of 
MSSE can be confirmed by detection of constitutional TGFBR1 mutations (see below). Although the 
tumors are invasive and can be locally destructive, distant metastases have not been reported. 
 
Figure 2. A multiple self-healing squamous epithelioma (MSSE) tumor that has the histological 
appearance of a well differentiated squamous cell carcinoma with invasion of the reticular dermis. 
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Figure 3. An involuting tumor with cornified “nests” coalescing into a keratin plug in the dermis. 
Tumors are most commonly treated with local surgical excision but many patients avoid 
treatment and prefer to await spontaneous regression despite the scars that can result [3]. Etretinate 
therapy has been reported to reduce tumor numbers in some patients [4,5]. Treatment with 
radiotherapy must be avoided because more numerous, more invasive tumors arise in previously 
irradiated skin [3,5,6]. 
In a study of 11 independently ascertained Scottish families including 62 affected family 
members, MSSE was found to segregate as an autosomal dominant trait [2]. This study was 
undertaken by Professor Malcom Ferguson-Smith, a clinical geneticist and the son of John 
Ferguson-Smith, the dermatologist who first described the condition. Of the 74 offspring of obligate 
carriers, 37 were affected and 37 unaffected; among affected offspring 19 were male and 18 female. 
2. Genetic Linkage 
Linkage studies using polymorphic DNA markers in 11 affected families (41 affected 
individuals and 110 of their first degree relatives) showed that MSSE segregates with markers for the 
long arm of chromosome 9 at 9q22.3q31) [7]. The MSSE locus was tightly linked to the polymorphic 
DNA marker D9S53 with a maximum lod score of 9.02 at a recombination fraction 0.03. 
Ten families were from Scotland and one was from the north east of England. Comparison of 
marker alleles segregating with MSSE revealed that the same haplotype of 9q22.3 markers was 
segregating with MSSE in 9 of these families [7–9] (Table 1). Four branches of the largest family 
(called Family GE in Reference [7] and Family 4 in Reference [9] were originally ascertained 
independently. Genealogical studies [2] revealed that the affected members of this family were all 
descended from a couple that married in west central Scotland in 1810. The affected members of the 
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2. Genetic Linkage
Linkage studies using polymorphic DNA markers in 11 affected families (41 affected individuals
and 110 of their first degree relatives) showed that MSSE segregates with markers for the long arm of
chromosome 9 at 9q22.3q31 [7]. The MSSE locu was tightly linked to the polymorphic DNA marker
D9S53 with a maximu lod score of 9.02 at a recombination fraction 0.03.
Ten families were from Scotland and n was from the north east of England. Comparison
of marker allel segr gating with MSSE rev aled that the same aplotype of 9q22.3 markers was
seg egating with MSSE in 9 of these famili s [7–9] (Table 1). Four branches of the largest family (called
Family GE in Reference [7] and Family 4 in Reference [9] were originally asc rtained independent .
Gen alogical studies [2] revealed that the affected members of this family w re all descended from a
coupl that married in west central Scotland in 1810. The affect d me bers of the 9 families must have
inherited the shared haplotype from a common a cestor th t lived over 200 years ago.
Th re was a surprising lack of recombination events in the shared hapl type. Th haplotype
has been inherited intact through many generations [7,8,10]. This lack of recombination precluded
precise localization of the genetic variants predisposing to MSSE. The haplotype shared by 38 affected
members of 7 families (families 4–10 in Table 1) spans about 9.9 Mb of the long arm of chromosome 9
and includes at least 138 genes. Haplotype comparisons revealed evidence for recombination events in
previous generations of two affected families. Affected members of families 2 and 18 (Table 1) only
shared part of the haplotype spanning 4 Mb of chromosome 9 centromeric to the XPAC gene, indicating
that the MSSE gene was likely to lie in this 4 Mb region [8,9].
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Table 1. Shared haplotypes in Scottish families with common ancestry (modified from Supplementary





D9S119 95867389-95867529 1 1 1
D9S197 95875618-95875968 2 2/4 * 2
D9S196 95906010-95906446 5 4/5 * 5
ZNF169CA 96264697-96265065 8 8 8
FBP1 (GA) 96474007-96474379 2 2 1/2 *
AFM070xb11 97021578-97065291 1 1 1
AFM086yf1 97365423-97402531 1 1 1
D9S280 97365423-97344962 2 2 2
FANCC CA Intr2 97912205-98079991 2/3 * 2 2/4 *
FANCC EcoRI 97912205-98079991 2 1/2 * 2
FANCC CA Intr1 97912205-98079991 1 1 1
AFM203WH8 * 98073744-98074099 1 1 1
PTC INT5 98205266-98270831 T T T
PTC INT9 98205266-98270831 C C C
PTC INT10 98205266-98270831 G G G
D9S1816 98276797-98277080 5 5 5/8 *
D9S287 98466090-98466414 3 3 3
AFMa350xgi 98544811-98545188 2 2 2
D9S1809 98558557-98558805 5 5 5
AFM023xh8 99032436-99032712 1 1/2 * 1
D9S1851 99570721-99571084 2 2 2
XPA (MspI) 100437192-100459691 A G G
D9S180 100649474-100649706 1 2 2
D9S6 100931590-100931609 A2 A1 A1
D9S173 101890198-101916471 2 4 2/4 *
D9S176 102058162-102058520 7 3/5 * 5
TGFBR1 103142351-103142640 p.(G52R) p.(N45S) p.(R414X)
ALDOB 104182842-104198062 1 1 1/2 *
D9S109 105566169-10556648 2 3 6
The dark shaded boxes indicate contiguous groups of markers defining the shared 4 Mb chromosome 9q22.3
haplotype conserved between families 2,4,5,6,7,8,9,10 and 18 and the 9.9 Mb haplotype shared by families 4–10.
The family numbers are from Reference [9]. The lighter shaded box indicates the location of the TGFBR1 gene
within the larger 9.9 Mb haplotype and shows the different TGFBR1 mutations found in each family or group of
families. * For loci where an unfavorable family structure precluded unambiguous identification of which allele was
segregating with the condition, both alleles shared by affected family members are shown.
3. Pathogenic TGFBR1 Sequence Variants Cause MSSE
Efforts to identify the disease gene with Sanger sequencing of many of the genes within the
conserved 9q22.3 haplotype were unsuccessful [11]. The advent of high-throughput massively parallel
sequencing made it possible to screen for pathogenic sequence variants in many more genes.
Exon array capture of coding sequences and high-throughput genomic sequencing from a 24 Mb
region of chromosome 9 that included the whole of the 9.9 Mb haplotype shared by most affected
Scottish families’ identified independent mutations in the transforming growth factor beta receptor
gene, TGFBR1, in three unrelated families [9]. Subsequent dideoxy sequencing of TGFBR1 identified
11 distinct monoallelic mutations in 18 affected families, firmly establishing TGFBR1 as the causative
gene. TGFBR1 mutations were found in all 67 affected individuals that were genotyped from the
18 families with mutations. The age of onset of a first tumor in mutation carriers was between 8 and
81 years. Sixteen asymptomatic mutation carriers were found (mean age 36.5 years, range 19–79 years).
The pathogenic sequence variants included mutations in the extracellular ligand-binding domain
and a series of truncating mutations (Figure 4). Since then, TGFBR1 mutations have been reported
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in 9 other families in the literature [6,12–16] or found through diagnostic testing (unpublished data).
These variants together with variants described in Reference [9] are shown in Figure 4. The c.122G > A
p.(Arg80X) variant has been found in three independently ascertained patients from New Zealand [9],
Switzerland [16], and the UK [6]. The frameshift variant c.980delC p. (Pro327GlnfsX8) variant has
been found in three Scottish families and the frameshift variant c.1059_1062del 6 ACTGinsCAATAA
p.(Leu354AsnfsX4) variant has been found in two families in Scotland.   
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Figure 4. Mutations in TGFBR1 in individuals with MSSE (modified from Reference [9] Domain
structure of the TGFβRI protein showing reported MSSE mutations [6,9,12–16] and unpublished data).
The MSSE mutations are shown above the protein while the locations of missense mutations reported
in Loeys Dietz syndrome [17–29] are indicated by asterisks below. The location of the c.1459C > T,
p.(Arg487Trp) and c.664G > A, p.(Gly222Arg) variants found in patients with both MSSE and Loeys
Dietz phenotypes are also shown. Functional domains are color-coded: extracellular ligand-binding
domain (yellow), transmembrane domain (green), glycine-serine-rich domain (red), cytoplasmic kinase
domain (blue). SP, signal peptide; TM, transmembrane domain.
No pathogenic TGFBR1 sequence variants or larger scale deletions or duplications of the TGFBR1
gene were detected in affected members of four families with familial self-healing skin tumors [9].
The etiology of the skin tumors in these families is unknown.
Analysis of DNA from micro-dissected tumors from MSSE patients with constitutional TGFBR1
mutations shows somatic loss of heterozygosity at the TGFBR1 locus with retention of the mutant allele
consistent with TGFBR1 behaving as a tumor suppressor gene [9,10]. Constitutional heterozygous
loss of function TGFBR1 mutations do not appear to have any effect on development, suggesting that
transforming growth factor beta (TGFβ) signaling is not seriously perturbed in most cells with a single
functional copy of the TGFBR1 gene. Tumors develop from skin keratinocytes where a “second hit”
has resulted in loss of the remaining functional TGFBR1 allele.
In a Tgfbr1 mouse model [30] carrying a p.Y378 * nonsense mutation heterozygous mutant mice
were morphologically indistinguishable from wild type mice. In this model, the mutant allele is
degraded by nonsense mediated mRNA decay. Homozygous mutant mice die during embryogenesis
due to defective vascularization. A macroscopic evaluation of the skin of fifteen 12-month-old
heterozygous Tgfbr1 mutant mice did not reveal any scars similar to those observed in human MSSE
patients after spontaneous regression of the skin tumors.
4. Digenic Inheritance: TGFBR1 and a Second Linked Locus on the Long Arm of Chromosome 9
The finding that TGFBR1 is the MSSE gene was unexpected because the TGFBR1 gene lies outside
the 4 Mb haplotype shared by all nine Scottish families with common ancestry (Table 1). It does,
Genes 2020, 11, 1410 6 of 12
however, lie within the 9.9 Mb haplotype shared by seven of the nine families [10]. The same TGFBR1
mutation p.(G52R) was found in all seven families with the larger haplotype. The two “recombinant”
families (families 2 and 18) that share only the shorter 4 Mb haplotype that does not extend to TGFBR1
have different TGFBR1 mutations (p.(N45S) and p.(R414X)). These findings indicate that a second
locus, within that part of the Scottish haplotype shared by all nine families, including families 2 and
18, is required for MSSE pathogenesis as it is very unlikely that all the families share the same rare
haplotype by chance. The rarity of this 4 Mb disease associated haplotype was confirmed by the
identification of nine additional rare sequence variants in the introns of five genes within the haplotype
in targeted sequencing studies in members of the Scottish families including families 2 and 18 [31].
In 231 unrelated healthy controls including 118 Scottish individuals, the minor allele frequency of the
nine variants ranged from 0 to 0.022.
The shared haplotype segregates with MSSE in families with missense variants in the extracellular
domain of the TGFBR1 and a family with a truncating nonsense mutation. The haplotype has not
been found in several other Scottish families [8] or in any families that are not of Scottish descent [11].
Despite this, it is likely that the etiology of the condition is the same in all families with MSSE caused
by mutations in TGFBR1. Permissive variants at the second locus that have arisen independently in
unrelated families will not be associated with shared haplotypes.
The evidence for digenic inheritance is strengthened by the remarkable lack of recombination
within the extended 9 Mb haplotype shared by all affected members of seven families. If mutations in
TGFBR1, which lies at the telomeric end of the haplotype, and rare variants at the centromeric end of
the haplotype are required for tumor development, ascertainment of affected individuals will select for
the intact haplotype. The condition is inherited as a high penetrance dominant trait because permissive
variants in TGFBR1 and the second linked locus are usually inherited together in affected families.
Structural chromosomal abnormalities, such as paracentric inversions, can cause local suppression
of recombination but we have observed recombination within the Scottish haplotype in two unaffected
family members with an affected parent indicating that it is unlikely that recombination is being
suppressed by a structural chromosomal abnormality (unpublished data).
Haplotype comparisons suggest the second locus lies proximal to the XPAC gene in 9q22.3 over
1.5 Mb from TGFBR1. As many of the MSSE TGFBR1 mutations are predicted to abolish expression of
TGFBR1, it is unlikely that the second locus is a TGFBR1 cis-regulatory element.
The second locus has not been identified with sequencing coding and non-coding sequences
within the shared 4 Mb haplotype but coverage has been incomplete [10,11,18].
5. MSSE Is Allelic to Loeys Dietz Syndrome Caused by TGFBR1 Mutations
Loeys Dietz syndrome is an autosomal dominant aortic aneurysm syndrome. The most typical
clinical signs include hypertelorism (widely spaced eyes), bifid uvula or cleft palate and aortic aneurysm
with increased tortuosity of the aorta and other major blood vessels. There is a substantial risk of aortic
dissection and aneurysms in other arteries [17]. Loeys Dietz syndrome can be caused by mutations
in TGFBR1 [18] and several other genes encoding for components of the TGFβ signaling pathway
including TGFBR2 [17–20], SMAD3 [32], TGFB2 [33,34] and TGFB3 [35,36].
The spectrum of TGFBR1 mutations in patients with Loeys Dietz syndrome [17–26,28,29,37] and
patients with MSSE is different (Figure 4). The great majority of TGFBR1 mutations in patients with
Loeys Dietz syndrome are missense variants clustered in or near the region of the gene that encodes the
cytoplasmic serine/threonine kinase domain. In-frame deletions in the kinase domain and duplications
have also been reported. In contrast, most of the mutations that have been found in MSSE patients
are truncating variants distributed throughout the gene or missense variants in the region of the
gene encoding the ligand-binding extracellular domain. Two of the truncating mutations have been
confirmed to abolish expression of the mutant mRNA in EBV-transformed lymphocytes from MSSE
patients [9]. TGFBR1 mRNA expression associated with other truncating sequence variants has not been
studied but the other variants also lie in regions of the gene where they would be expected to promote
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nonsense mediated decay of mutant mRNA. TGFβR1 protein (extracellular domain) has been detected
immunohistochemically in tumors from two affected individuals (one had a splice junction mutation
(c.806-2A > C) and the other an extracellular domain missense mutation (p.Gly52Arg)) indicating that
in these tumors the mutant proteins were translated and localized to the plasma membrane. If, as these
observations suggest, the mRNA product of the TGFBR1 c.806-2A > C splice acceptor variant is not
subject to nonsense mediated decay, the mutant protein would be predicted to lack large parts of the
kinase domain abrogating signaling (see below).
Splice junction mutations have been described in patients with MSSE and Loeys Dietz syndrome.
Fujiwara and colleagues [38] compared the effects on differential mRNA splicing of a splice donor site
variant in TGFBR1 (c.973 + 1G > A) found in a Japanese patient with familial Loeys Dietz syndrome
with the effects of the splice acceptor site variant (c.806-2A > C) discussed above. Ex vivo splicing
and functional assays performed in mammalian cells showed that the Loeys Dietz variant generated
two types of in-frame transcription products producing functionally inactive proteins whereas the
MSSE variant produced an out-of-frame transcript. These results are consistent with the distribution of
other mutations, suggesting that dominant-negative variants in the serine threonine kinase domain of
TGFBR1 cause Loeys Dietz syndrome whereas truncating variants cause MSSE.
In silico modeling of the extracellular domain of the TGFβ signaling complex shows that most
missense variants found in MSSE patients result in amino-acid substitutions affecting residues that lie
along the interface at which TGFβRI interacts with the previously assembled TGFβRII and TGFβ or at
the interface at which TGFβRI interacts TGFβ directly [9]. These variants may therefore interfere with
recruitment of mutated TGFβRI to the receptor complex.
We know of over 80 patients with MSSE carrying truncating mutations in TGFBR1 or missense
mutations in the ligand-binding extracellular domain of the gene. None of these patients have been
reported to have thoracic aortic aneurysms. The TGFBR1 mutations, found in most patients with MSSE,
are not associated with a high penetrance predisposition to the development of aortic aneurysms.
Heterozygous loss of function mutations found in MSSE families do not cause Loeys Dietz
syndrome. This is confirmed by studies in mice in which heterozygotes for null and missense TGFBR1
mutations have been produced [30,39]. Only the mice with a TGFBR1 missense mutation in the
cytoplasmic serine/threonine kinase domain had the Loeys Dietz phenotype [39].
The mechanism by which missense kinase domain TGFBR1 mutations cause Loeys Dietz syndrome
is complex and incompletely understood. TGFBR1 mutations associated with Loeys Dietz syndrome
were found to be inactivating for canonical TGFβ signaling in co-transfection studies with a luciferase
reporter or EGFP-tagged SMAD2 in HEK293 cells [40]. Heterozygous mutant cells from transgenic mice
had diminished signaling in response to exogenous TGFβ in vitro and they maintained normal levels
of Smad2 phosphorylation under steady-state culture conditions, suggesting a chronic compensation.
Analysis of TGFβ signaling in the aortic wall in vivo revealed progressive upregulation of Smad2
phosphorylation and TGFβ target gene output, which paralleled worsening of aneurysm pathology
and coincided with upregulation of TGFβ1 ligand expression [38].
6. TGFBR1 Variants in MSSE Patients with Aortic Aneurysms
Since TGFBR1 mutations were first described in patients with MSSE, two patients with MSSE and
aortic aneurysms have been described. Both patients carry missense sequence variants in the region of
the gene encoding the cytoplasmic serine/threonine kinase domain. The location of these variants is
shown in Figure 4.
A 50-year-old woman with MSSE was found to carry a missense mutation in the serine kinase
domain of TGFBR1, previously reported only in Loeys Dietz syndrome (c.1459C > T, p.Arg487Trp) [14].
She had five confirmed keratoacanthoma-like skin lesions with the first lesion occurring when she was
30 years old. She had one first-degree relative with MSSE. She had mild hypertelorism and a broad
uvula consistent with Loeys Dietz syndrome. Computed tomography angiogram demonstrated focal
aneurysms of the internal carotid arteries and widespread arterial tortuosity.
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A 56 year old man with a five year history of keratoacanthomas over his arms, face and scalp was
found to be carrying a TGFBR1 missense variant (c.664G > A, p.(Gly222Arg)), resulting in substitution
of a glycine residue by an arginine at position 222 within the serine/threonine kinase domain [15].
At least seven skin tumors had been excised and diagnosed histologically and he estimated that a
further 30 had resolved without treatment. He had an aortic root and valve replacement for aortic
regurgitation and aortic root dilatation diagnosed when he was 46 years old. The TGFBR1 c.664G > A,
p.(Gly222Arg)) variant is classified as a variant of uncertain significance using the American College
of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP)
standards and guidelines for the interpretation of sequence variants [41] but moderate evidence of
pathogenicity is provided by its location in a mutational hot spot and multiple lines of computational
evidence suggest that the amino acid substitution will have a deleterious effect.
Neither of these patients carry the “at risk” haplotype shared by most MSSE families with Scottish
ancestry but these findings are consistent with a requirement for inherited permissive variants at a
second locus for the development of tumors in MSSE patients.
7. The Second Locus and the Distinctive Spectrum of TGFBR1 Mutations in Loeys Diets
Syndrome and MSSE
If uncommon inherited variants at a second locus are required for development of tumors in
TGFBR1 mutation carriers then only a small proportion of patients with TGFBR1 mutations ascertained
because they have Loeys Dietz syndrome would be expected to have MSSE. Few of them would have
inherited a permissive variant at the second locus.
All patients ascertained with MSSE would be expected to have permissive variants at the second
locus and so the frequency of the different classes of pathogenic TGFBR1 variants in these patients
should reflect their frequency in the general population. It is likely that the TGFBR1 variants that
predispose to Loeys Dietz syndrome are less common than other classes of pathogenic variants in the
gene. The reproductive fitness of carriers of TGFBR1 variants that cause Loeys Dietz syndrome is likely
to be reduced because of the substantial risk of early death from aortic dissection and other vascular
complications of the condition.
Pathogenic TGFBR1 sequence variants are rare and so estimation of the relative frequency of
subclasses of these variants in the general population is difficult, even with the large human variant
datasets that are now available [42].
8. Keratoacanthomas/Squamous Cell Carcinomas in Patients Treated with an TGFβ Monoclonal
Antibody
In a phase 1 study using GC1008 (Fresolimumab), a human anti-TGFβ monoclonal antibody,
to treat advanced malignant melanoma or renal cell carcinoma, 4 out of 29 patients developed
keratoacanthoma or squamous cell carcinoma-like skin tumors [43]. Multiple skin tumors developed.
The lesions that were not removed resolved spontaneously over a period of weeks or months after
treatment was discontinued. The skin tumors occurred in patients with greater GC1008 exposure,
patients treated at higher doses, receiving extended treatment, or both.
A higher proportion of patients (14%) developed skin tumors than would be expected if they
had a predisposition to tumor development conferred by variants at the TGFBR1 linked locus that
predispose to MSSE.
In MSSE loss of heterozygosity, studies suggest that tumors arise from cells with biallelic
inactivation of TGFBR1 in a microenvironment with stromal cells with mono-allelic TGFBR1 mutations.
Anti-TGFβ monoclonal antibodies seem to induce development of similar tumors in the absence of
permissive variants at the second MSSE locus. Anti-TGFβ monoclonal antibodies may have a more
significant effect on TGFβ signaling in stromal cells than inherited mono-allelic TGFBR1 mutations.
Anti-TGFβ monoclonal antibodies may also inhibit signaling in tumor keratinocytes through pathways
that do not require TGFβR1.
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9. Conclusions
Identification of TGFBR1 mutations in MSSE patients has had some clinical benefits. MSSE can be
diagnosed earlier and more reliably, resulting in improved treatment with avoidance of potentially
damaging radiotherapy. Testing for pathogenic TGFBR1 variants can help distinguish between MSSE
and conditions such Lynch syndrome in which multiple keratoacanthomas can occur. Evidence from
the spectrum of TGFBR1 mutations in MSSE shows that truncating mutations detected in patients with
thoracic aortic aneurysms in the course of diagnostic testing must be viewed with caution and not
used as the basis of predictive tests for relatives.
TGFβ signaling has diverse effects on the behavior of epithelial tumor cells and the many
stromal cell types that generate and condition the microenvironment in which tumors develop [44].
The mechanisms by which inherited TGFBR1 mutations cause invasive tumors that consistently resolve
spontaneously have still to be elucidated. Whether tumor resolution is due to immunological
mechanisms or to intrinsic properties, the tumor cells or their microenvironment is unknown.
TGFβ1 exhibits biphasic actions in murine skin squamous cell carcinomas: suppressing early tumor
growth but enhancing malignant conversion. It is tempting to speculate that the TGFBR1 mutations in
MSSE have a reciprocal effect, promoting the early stages of tumor development [45]. Identification of
the second TGFBR1 linked locus is likely to improve our understanding of pathogenesis of tumors in
MSSE and related sporadic tumors. Somatic TGFBR1 mutations are common in sporadic squamous cell
carcinomas of the skin [46]. In a recent study of squamous cell carcinomas of the skin combining single
cell RNA-seq with other methods providing spatial data, it was possible to define tumor and stomal
cell populations and the communication network that they engage in cancer [47]. Application of these
technologies to tumors from MSSE patients would be likely to yield fascinating results.
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